About US
Contact us
-
GSK adds Bristol-Myers pipeline drugs to challenge Gilead in HIVIt wasn't all that long ago that GlaxoSmithKline ($GSK) was considering a spinoff for its HIV drugs division,ViiV Healthcare. Now, though, the company is hanging on tight to that business--and buildin2015/12/28
-
Merck's Keytruda lines up its survival data for stepped-up battle with BMS' OpdivoThe rivalry is heating up between Merck & Co.'s ($MRK) immuno-oncology drugKeytrudaand its counterpart from Bristol-Myers Squibb ($BMY),Opdivo, in lung cancer. Long expected to dominate, Opdivo ha2015/12/28
-
Brace yourselves: The drug pricing brouhaha isn't dying downWho's tired of talking about drug prices? Many pharma types would raise their hands at that question. It was already a sore subject, what with Gilead Sciences' ($GILD) infamous $1,000-per-pill hepatit2015/12/25
-
Think we've seen the last of pharma's M&A tidal wave? Think againIf you think 2015 was a big year in pharma M&A, just wait. That train won't be slowing down any time soon, industry watchers say. On the contrary, they're expecting even more deal activity next ye2015/12/25
-
Shkreli charges prompt Nasdaq to delist KaloBiosMartin Shkrelihas already been ousted as CEO of KaloBios ($KBIO). And now, Nasdaq plans to delist the company, citing Shkreli's recent arrest on fraud and looting charges as one reason for the move.2015/12/24
-
What's the calendar bringing biopharma next year? Our top 5 ideasWinter days are short and dark. December is winding down. If you're not already on a holiday break, you likely will be soon. So, it's a good time to take a minute to think about what's ahead in the ne2015/12/24
-
Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2sTheNew England Journal of Medicinehas laid out the data from a cardiovascular outcomes trial of Sanofi's ($SNY) GLP-1 diabetes hopefulLyxumia, and the good news for the French drugmaker is that the dr2015/12/4
-
Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drugJapanis considering capping the price of biosimilars at 70% of the reference drug, while lowering the price cap on generics from 60% to 50% of the price for the drugs they copy. The government has pus2015/12/4
-
Can Pfizer finally orchestrate a winning megamerger after so many disappointments?Pfizer's ($PFE) decision to buy Allergan ($AGN) wasn't much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEOIan Read's desired tax inversion.2015/12/3
-
Novo touts SGLT2-topping data for blockbuster VictozaSGLT2 drugs may be in the diabetes spotlight thanks to recent data showing that one of them--Eli Lilly ($LLY) andBoehringer Ingelheim'sJardiance--could cut cardiovascular risks. But Novo Nordisk ($NVO2015/12/3